Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You accept for the main domain ...

The calprotectin testing market has gained significant attention in recent years, owing to the rising awareness of gastrointestinal diseases and the importance of non-invasive diagnostic methods.

Interleukin-23 (IL-23) and its receptor are implicated in disease progression. IBD is associated with intestinal inflammation-mediated recruitment of neutrophils. Several neutrophil-associated ...

(100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in ...

Beam reports breakthrough results from BEAM-101's early-stage trial for severe sickle cell disease. Read more here.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of ...

Rates of grade III/IV acute GVHD at 3 months were 3% with cyclophosphamide-cyclosporin prophylaxis and 10% with standard ...

Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...